• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性阻塞性肺疾病的死亡率:病因、危险因素和预防。

Mortality in COPD: causes, risk factors, and prevention.

机构信息

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

出版信息

COPD. 2010 Oct;7(5):375-82. doi: 10.3109/15412555.2010.510160.

DOI:10.3109/15412555.2010.510160
PMID:20854053
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7273182/
Abstract

Chronic obstructive pulmonary disease (COPD) is a leading and increasing cause of death, the extent of which is underestimated as a consequence of underdiagnosis and underreporting on death certificates. Data from large trials, such as the Lung Health Study, Towards a Revolution in COPD Health (TORCH), Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT), European Respiratory Society Study on Chronic Obstructive Pulmonary Disease (EUROSCOP), and Inhaled Steroids in Obstructive Lung Disease (ISOLDE), have shown that the causes of death in patients with mild COPD are predominantly cancer and cardiovascular disease, but as COPD severity increases, deaths due to non-malignant respiratory disease are increasingly common. In practice, mortality of patients with COPD can be predicted by a variety of measures including: forced expiratory volume in one second (FEV(1)), the ratio of inspiratory and total lung capacities, exercise capacity, dyspnea scores, and composite indices such as the body-mass index (B), degree of airflow obstruction (O), degree of functional dyspnea (D), and exercise capacity (E) (BODE) index. Smoking cessation improves survival in COPD patients, and in select patients with advanced disease, oxygen therapy, lung volume reduction surgery, or lung transplantation may also improve survival.

摘要

慢性阻塞性肺疾病(COPD)是主要的致死病因,且其致死人数呈上升趋势。由于诊断不足和死亡证明报告不足,其实际致死人数被低估。大型试验的数据,如肺健康研究(Lung Health Study)、COPD 健康革命研究(TORCH)、噻托溴铵对功能潜在长期影响的认识研究(UPLIFT)、欧洲呼吸学会 COPD 研究(EUROSCOP)和吸入性皮质类固醇治疗阻塞性肺病(ISOLDE)表明,轻度 COPD 患者的主要死因是癌症和心血管疾病,但随着 COPD 严重程度的增加,非恶性呼吸道疾病导致的死亡越来越常见。实际上,多种指标都可以预测 COPD 患者的死亡率,包括:第一秒用力呼气量(FEV1)、吸气量与肺总量之比、运动能力、呼吸困难评分以及体质量指数(BMI)、气流阻塞程度(O)、功能性呼吸困难程度(D)和运动能力(E)的综合指数(BODE 指数)。戒烟可改善 COPD 患者的生存状况,对于一些晚期疾病患者,氧疗、肺减容术或肺移植也可能改善生存状况。

相似文献

1
Mortality in COPD: causes, risk factors, and prevention.慢性阻塞性肺疾病的死亡率:病因、危险因素和预防。
COPD. 2010 Oct;7(5):375-82. doi: 10.3109/15412555.2010.510160.
2
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.慢性阻塞性肺疾病中的体重指数、气流受限、呼吸困难及运动能力指数
N Engl J Med. 2004 Mar 4;350(10):1005-12. doi: 10.1056/NEJMoa021322.
3
Surrogates of mortality in chronic obstructive pulmonary disease.慢性阻塞性肺疾病死亡率的替代指标。
Am J Med. 2006 Oct;119(10 Suppl 1):54-62. doi: 10.1016/j.amjmed.2006.08.008.
4
The Ability of Different Scoring Systems to Predict Mortality in Chronic Obstructive Pulmonary Disease Patients: A Prospective Cohort Study.不同评分系统预测慢性阻塞性肺疾病患者死亡率的能力:一项前瞻性队列研究。
Respiration. 2019;98(6):495-502. doi: 10.1159/000502826. Epub 2019 Oct 30.
5
Mortality in COPD: Role of comorbidities.慢性阻塞性肺疾病中的死亡率:合并症的作用。
Eur Respir J. 2006 Dec;28(6):1245-57. doi: 10.1183/09031936.00133805.
6
The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.以患者为中心的结局在慢性阻塞性肺疾病病程中的作用:长期研究如何增进我们的理解。
Am J Med. 2006 Oct;119(10 Suppl 1):63-72. doi: 10.1016/j.amjmed.2006.08.009.
7
Exercise Ventilatory Inefficiency Adds to Lung Function in Predicting Mortality in COPD.运动通气效率低下在预测慢性阻塞性肺疾病(COPD)死亡率方面增加了肺功能的预测价值。
COPD. 2016 Aug;13(4):416-24. doi: 10.3109/15412555.2016.1158801. Epub 2016 Apr 14.
8
Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index.慢性阻塞性肺疾病患者预后评估的扩展:更新后的BODE指数和ADO指数。
Lancet. 2009 Aug 29;374(9691):704-11. doi: 10.1016/S0140-6736(09)61301-5.
9
Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.噻托溴铵。关于其在慢性阻塞性肺疾病患者中作为维持治疗药物应用的综述。
Treat Respir Med. 2004;3(4):247-68. doi: 10.2165/00151829-200403040-00005.
10
β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT.β受体阻滞剂治疗中度慢性阻塞性肺疾病合并心血管风险增高患者的临床结局。SUMMIT 的一项观察性亚研究。
Ann Am Thorac Soc. 2018 May;15(5):608-614. doi: 10.1513/AnnalsATS.201708-626OC.

引用本文的文献

1
Muscle Wasting and Treatment of Dyslipidemia in COPD: Implications for Patient Management.慢性阻塞性肺疾病中的肌肉萎缩与血脂异常治疗:对患者管理的影响
Biomedicines. 2025 Jul 24;13(8):1817. doi: 10.3390/biomedicines13081817.
2
Examining the mediating function of SIRI in the association between LC9 and chronic obstructive pulmonary disease.研究SIRI在LC9与慢性阻塞性肺疾病之间关联中的中介作用。
Front Med (Lausanne). 2025 Jul 9;12:1606864. doi: 10.3389/fmed.2025.1606864. eCollection 2025.
3
Impacts of COPD exacerbation history on mortality and severe cardiovascular events among patients with COPD in China: a retrospective cohort study.慢性阻塞性肺疾病(COPD)加重病史对中国COPD患者死亡率和严重心血管事件的影响:一项回顾性队列研究
Respir Res. 2025 Jul 23;26(1):252. doi: 10.1186/s12931-025-03316-4.
4
Clinical and socioeconomic parameters as predictors for longer hospital stay and mortality in COPD.作为慢性阻塞性肺疾病(COPD)患者住院时间延长和死亡率预测指标的临床及社会经济参数
Chron Respir Dis. 2025 Jan-Dec;22:14799731251355445. doi: 10.1177/14799731251355445. Epub 2025 Jun 29.
5
Prognostic risk profiling in COPD using Global Initiative for Chronic Obstructive Lung Disease 2023 ABE and comorbidity assessment: evidence from a register-based COPD cohort.使用慢性阻塞性肺疾病全球倡议组织2023年ABE和合并症评估对慢性阻塞性肺疾病进行预后风险评估:来自基于登记的慢性阻塞性肺疾病队列的证据
J Glob Health. 2025 May 23;15:04152. doi: 10.7189/jogh.15.04152.
6
Impact of COPD and sarcopenia on all-cause and respiratory mortality in US adults: NHANES 1999-2018.慢性阻塞性肺疾病(COPD)和肌肉减少症对美国成年人全因死亡率和呼吸死亡率的影响:1999 - 2018年美国国家健康与营养检查调查(NHANES)
BMC Pulm Med. 2025 May 9;25(1):223. doi: 10.1186/s12890-025-03675-0.
7
Long-term exposure to smoke PM and COPD caused mortality for elderly people in the contiguous United States.在美国本土,长期接触烟雾细颗粒物和慢性阻塞性肺疾病会导致老年人死亡。
Environ Int. 2025 May;199:109513. doi: 10.1016/j.envint.2025.109513. Epub 2025 May 1.
8
Comparison of self-reported and job-exposure matrix assessed workplace inhalant exposures and their association with obstructive airways disease.自我报告与职业暴露矩阵评估的工作场所吸入性暴露的比较及其与阻塞性气道疾病的关联。
Sci Rep. 2025 Apr 23;15(1):14099. doi: 10.1038/s41598-025-95923-w.
9
The usefulness of Charlson Comorbidity Index (CCI) scoring in predicting all-cause mortality in Outpatients with Clinical Diagnoses of COPD.查尔森合并症指数(CCI)评分在预测慢性阻塞性肺疾病(COPD)临床诊断门诊患者全因死亡率方面的效用。
J Multimorb Comorb. 2025 Jan 27;15:26335565251315876. doi: 10.1177/26335565251315876. eCollection 2025 Jan-Dec.
10
Validation of new predictors of mortality and BODE index variants in patients with COPD at moderate altitude.中度海拔慢性阻塞性肺疾病患者死亡率新预测指标及BODE指数变体的验证
ERJ Open Res. 2025 Jan 27;11(1). doi: 10.1183/23120541.00333-2024. eCollection 2025 Jan.

本文引用的文献

1
Accuracy of death certificates in COPD: analysis from the TORCH trial.慢性阻塞性肺疾病死亡证明的准确性:来自 TORCH 试验的分析。
COPD. 2010 Jun;7(3):179-85. doi: 10.3109/15412555.2010.481695.
2
Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease.噻托溴铵治疗慢性阻塞性肺疾病4年试验(UPLIFT)中的死亡率
Am J Respir Crit Care Med. 2009 Nov 15;180(10):948-55. doi: 10.1164/rccm.200906-0876OC. Epub 2009 Sep 3.
3
Disease-specific survival benefit of lung transplantation in adults: a national cohort study.成人肺移植的疾病特异性生存获益:一项全国队列研究。
Am J Transplant. 2009 Jul;9(7):1640-9. doi: 10.1111/j.1600-6143.2009.02613.x.
4
Systemic manifestations and comorbidities of COPD.慢性阻塞性肺疾病的全身表现及合并症
Eur Respir J. 2009 May;33(5):1165-85. doi: 10.1183/09031936.00128008.
5
A 4-year trial of tiotropium in chronic obstructive pulmonary disease.噻托溴铵用于慢性阻塞性肺疾病的4年试验。
N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.
6
Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD?循环纤维连接蛋白与C反应蛋白比值及死亡率:慢性阻塞性肺疾病中的一种生物标志物?
Eur Respir J. 2008 Dec;32(6):1451-7. doi: 10.1183/09031936.00153207. Epub 2008 Sep 17.
7
Longitudinal change in the BODE index predicts mortality in severe emphysema.BODE指数的纵向变化可预测重度肺气肿患者的死亡率。
Am J Respir Crit Care Med. 2008 Sep 1;178(5):491-9. doi: 10.1164/rccm.200709-1383OC. Epub 2008 Jun 5.
8
C-reactive protein levels and survival in patients with moderate to very severe COPD.中重度至极重度慢性阻塞性肺疾病患者的C反应蛋白水平与生存率
Chest. 2008 Jun;133(6):1336-1343. doi: 10.1378/chest.07-2433. Epub 2008 Mar 13.
9
Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data.慢性阻塞性肺疾病患者双侧肺移植与单肺移植后的生存率:登记数据的回顾性分析
Lancet. 2008 Mar 1;371(9614):744-51. doi: 10.1016/S0140-6736(08)60344-X.
10
Determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease.慢性阻塞性肺疾病患者肺移植生存获益的决定因素。
Am J Respir Crit Care Med. 2008 May 15;177(10):1156-63. doi: 10.1164/rccm.200708-1283OC. Epub 2008 Feb 28.